Prior lines of treatments in CP CML cohort
| Prior treatment . | Lines of therapy at ponatinib initiation, n . | Total, n (%) (N = 51) . | ||||
|---|---|---|---|---|---|---|
| 2nd (n = 4) . | 3rd (n = 17) . | 4th (n = 16) . | 5th (n = 6) . | >6th (n = 8) . | ||
| Imatinib | 2 | 15 | 13 | 6 | 8 | 44 (86.2) |
| Dasatinib | 1 | 11 | 17 | 6 | 8 | 43 (84.3) |
| Nilotinib | 1 | 6 | 15 | 6 | 9 | 37 (72.5) |
| Bosutinib | 0 | 0 | 0 | 1 | 0 | 1 (2.0) |
| Other* | 0 | 2 | 3 | 5 | 15 | 25 (49.0) |
| Prior treatment . | Lines of therapy at ponatinib initiation, n . | Total, n (%) (N = 51) . | ||||
|---|---|---|---|---|---|---|
| 2nd (n = 4) . | 3rd (n = 17) . | 4th (n = 16) . | 5th (n = 6) . | >6th (n = 8) . | ||
| Imatinib | 2 | 15 | 13 | 6 | 8 | 44 (86.2) |
| Dasatinib | 1 | 11 | 17 | 6 | 8 | 43 (84.3) |
| Nilotinib | 1 | 6 | 15 | 6 | 9 | 37 (72.5) |
| Bosutinib | 0 | 0 | 0 | 1 | 0 | 1 (2.0) |
| Other* | 0 | 2 | 3 | 5 | 15 | 25 (49.0) |
Chemotherapy, immunotherapy, or clinical trial.